Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States

Prostatype Genomics announces that the company and Professor E. David Crawford, MD, an internationally recognized expert in prostate cancer, will be the first US urologist with access to the Prostatype® testing service for clinical use. Providing early access and partnering with Professor Crawford in preparation for release nationwide will help ensure that urologist’s expectations are met when launching this next generation of prognostic testing to benefit patients battling prostate cancer.

Prostatype Genomics has recently communicated the fulfillment of several key regulatory milestones required for market entry in the United States, the world’s largest and most important market for prostate cancer prognostic biomarkers, currently valued at approximately 200 MUSD annually. These milestones include the acquisition of a CLIA license and CAP accreditation clearing the way for Prostatype’s® commercial availability in the United States. In addition, reimbursement by Medicare is expected later this year.

Professor Crawford, is an internationally recognized expert in urologic cancers, in particular, prostate cancer. He is an active member of many national and international organizations, including the American Society of Clinical Oncology, The American Urological Association (AUA), and the American Association for the Advancement of Science.

He is the Jack A. Vickers Director of Prostate Cancer Research at the University of California San Diego and professor of urology in the Department of Urology. Professor Crawford has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians. Professor Crawford has served as editor in chief of Grand Rounds in Urology since June of 2019.

Fredrik Persson, CEO of Prostatype Genomics, comments:
“We are proud to announce this important collaboration with Professor Crawford, one of the leading and most respected urologists in United States and internationally. Professor Crawford’s vast experience within the field of prostate cancer, including molecular biomarkers, will provide guidance to Prostatype Genomics as part of the initial commercial launch of Prostatype® in the United States, which will begin shortly upon completion of the final step of the regulatory process. Professor Crawford’s input, recommendations, and clinical experience with Prostatype® will set a benchmark for our activities in United States. We could not have asked for a higher qualified, knowledgeable, and respected urologist in preparation for entering the US market.”

Professor Crawford comments:
“Prostatype® is an innovative prognostic genomic biomarker for prostate cancer, and I am looking forward to gaining clinical experience with this test. The unique and standout feature of Prostatype® compared to prognostic biomarkers for prostate cancer that are currently available in the United States is that Prostatype® focuses on gene expressions mainly expressed in embryonic stem cells. There is such strong scientific evidence supporting the accuracy of Prostatype® that I dare to say that I believe that it will be the most promising biomarker to be launched in the United States in 2024. I will start using Prostatype® within my practice, and hope that my experience and feedback provided to Prostatype Genomics will guide the company in the United States in the best way possible from a clinical point of view.”

For more information, please contact:
Fredrik Persson, CEO Prostatype Genomics AB
Telephone: +46 (0)73 049 77 01
Email: [email protected]

About Prostatype Genomics AB
Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.